Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

110.23 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 22,708
Open 110.23
Bid (Size) 108.10 (17)
Ask (Size) 108.40 (1)
Prev. Close 110.23
Today's Range 110.23 - 110.23
52wk Range 62.07 - 119.96
Shares Outstanding 1,253,809,440
Dividend Yield 2.79%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Trump Administration Weighs Deep Cuts To Domestic HIV Prevention Programs, Gilead Stock Slides
HHS is considering major cuts to federal HIV prevention funding as part of a CDC reorganization, potentially affecting programs like PrEP. Experts warn the move could hinder efforts to combat the... 
Via Benzinga
Topics Government
Exposures Political
A Look Back at Therapeutics Stocks’ Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack
Let’s dig into the relative performance of Vertex Pharmaceuticals (NASDAQ:VRTX) and its peers as we unravel the now-completed Q4 therapeutics earnings season. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
+20.0%
+20.0%
1 Month
+4.7%
+4.7%
3 Month
+18.8%
+18.8%
6 Month
+32.7%
+32.7%
1 Year
+50.5%
+50.5%

More News

Read More
Unpacking the Latest Options Trading Trends in Gilead Sciences
Via Benzinga
Gilead Sciences - Leader In HIV Medicines
Via Talk Markets
Topics Stocks / Equities
Exposures COVID-19
The Analyst Verdict: Gilead Sciences In The Eyes Of 14 Experts
Via Benzinga
Gilead Sciences's Options: A Look at What the Big Money is Thinking
Via Benzinga
P/E Ratio Insights for Gilead Sciences
Via Benzinga
Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
Via Benzinga
Friday's session: top gainers and losers in the S&P500 index
Via Chartmill
Is Gilead Sciences Gaining or Losing Market Support?
Via Benzinga
GILEAD SCIENCES INC (NASDAQ:GILD) Exhibits Quality Stock Traits. Here's Why.
Via Chartmill
Gilead Presents New HIV Treatment And Cure Research Data
Via Benzinga
Gilead Presents New HIV Treatment and Cure Research Data at CROI 2025, Including an Investigational Long-Acting, Twice-Yearly Therapy Option
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Unusual Options Activity
Via Benzinga
First Clinical Data for Gilead’s Investigational Once-Yearly Lenacapavir for HIV Prevention Presented at CROI 2025 and Published in The Lancet
From Gilead Sciences, Inc.
Via Business Wire
These 3 Dividend Stocks Jumped 15% in a Month—More to Come?
Via MarketBeat
Gilead Sciences To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
The Top Nasdaq-100 Stock in 2025 Has Nothing to Do With Artificial Intelligence (AI)
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
1 Value Stock with Exciting Potential and 2 to Ignore
Via StockStory
Best And Worst Performing S&P 500 Stocks Since Trump's Election Win
Via Benzinga
Topics Government Stocks
Exposures Political US Equities
Salesforce Earnings Top Views. Software Stock Falls On Weak Revenue Outlook.
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
European Medicines Agency Validates Gilead’s Marketing Authorization Application and EU-Medicines for All Application for Twice-Yearly Lenacapavir for HIV Prevention
From Gilead Sciences, Inc.
Via Business Wire
What To Expect From Myriad Genetics’s (MYGN) Q4 Earnings
Via StockStory
Gilead Sciences: 4 Reasons This Stock Has Much More To Rise
Via MarketBeat
Topics Death
Exposures Death

Frequently Asked Questions

Is Gilead Sciences publicly traded?
Yes, Gilead Sciences is publicly traded.
What exchange does Gilead Sciences trade on?
Gilead Sciences trades on the Nasdaq Stock Market
What is the ticker symbol for Gilead Sciences?
The ticker symbol for Gilead Sciences is GILD on the Nasdaq Stock Market
What is the current price of Gilead Sciences?
The current price of Gilead Sciences is 110.23
When was Gilead Sciences last traded?
The last trade of Gilead Sciences was at 03/18/25 04:00 PM ET
What is the market capitalization of Gilead Sciences?
The market capitalization of Gilead Sciences is 138.21B
How many shares of Gilead Sciences are outstanding?
Gilead Sciences has 138B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.